Literature DB >> 17639746

Osteoporosis preventive care in white and black women in community family medicine settings.

Margaret L Gourlay1, Leigh F Callahan, John S Preisser, Philip D Sloane.   

Abstract

BACKGROUND: Osteoporosis has been studied predominantly in white postmenopausal women.
MATERIALS AND METHODS: We performed a cross-sectional survey of a random sample of 400 women aged 45 years and older enrolled in a family medicine community-based research network. Participants responded to 42 items regarding osteoporosis screening and prevention during primary care visits. Odds ratios were calculated comparing black versus white women, adjusting for age, weight, fracture history, family history of osteoporosis, and practice site.
RESULTS: Compared with black women, white women had 5.96 (95% CI 3.01, 11.79) times the adjusted odds of having a past bone density test, 2.97 (95% CI 1.57, 5.60) times the odds of discussing osteoporosis with their doctor, and 2.42 (95% CI 1.30, 4.50) times the odds of a physician recommendation to take calcium.
CONCLUSIONS: Disparities in osteoporosis preventive care were found between black and white women, after adjustment for other osteoporosis risk factors.

Entities:  

Mesh:

Year:  2007        PMID: 17639746     DOI: 10.1097/SMJ.0b013e318038d45e

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

1.  The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders.

Authors:  D L Kelly; C S Myers; M T Abrams; S Feldman; J Park; R P McMahon; J-C Shim
Journal:  Osteoporos Int       Date:  2010-06-09       Impact factor: 4.507

2.  The effect modification of supplemental insurance on the relationship between race and bone mineral density screening in female Medicare beneficiaries.

Authors:  Ji Won Yoo; Shunichi Nakagawa; Sulgi Kim
Journal:  J Immigr Minor Health       Date:  2012-12

3.  Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.

Authors:  Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

4.  Effect of the women's health initiative on prescription anti-osteoporosis medication utilization.

Authors:  J F Farley; S J Blalock; R R Cline
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 4.507

5.  Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.

Authors:  Jeffrey R Curtis; Leslie A McClure; Elizabeth Delzell; Virginia J Howard; Eric Orwoll; Kenneth G Saag; Monika Safford; George Howard
Journal:  J Gen Intern Med       Date:  2009-06-24       Impact factor: 5.128

6.  Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.

Authors:  Tao Gu; Debra F Eisenberg Lawrence; Judith J Stephenson; Jingbo Yu
Journal:  Clin Interv Aging       Date:  2016-02-15       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.